Expression Of γ-synuclein And TFPI-2 In Non-small-cell Lung Cancer And Its Clinical Significance Study

1 AimsLung cancer is the major diseases threatening human life, its incidence and mortality rates are increasing every year.y-synuclein is a natural non-folded protein encoded by the human y-synuclein gene(SNCG).It is a recognized molecular markers of breast cancer. Recently studies found that it expressed abnormally highly in ovarian cancer, digestive tumors, particularly in advanced tumors expressed higher. It is expected to become an effective tumor marker. Literature at home and abroad about the y-Synuclein in non-small cell lung carcinoma and its clinical significance are reported less.Tissue factor pathway inhibitor 2 (TFPI-2) belongs to Kunitz-type serine protease inhibitor family of proteins, is a newly discovered serine protease inhibitor, with a variety of tumors, inhibit tumor cell invasion and metastasis.Its inhibition of tumor cell growth and the mechanism of invasion and metastasis become research hotspot in recent years. There are several papers about TFPI-2 expression in NSCLC in foreign countries, but in our country there is none.In view of the above study, the purpose of present study by immunohistochemical methods is exploring the expression of TFPI-2 and y-synuclein in NSCLC and the occurrence, development, and transfer mechanisms of NSCLC,providing experimental evidence for NSCLC diagnosis, treatment and prognosis evaluation.2 Study Object and Methods2.1 Study object Specimen (study group) were collected from NSCLC patients operated in the horacic surgery resection of the first affiliated hospital of zhengzhou university from January 2006 to December 2008,the total example is 60,all patients has not performed any anti-tumor therapy, and confirmed by pathologists.According to the U.S.Joint Committee on Cancer Classification (AJCC) and the International Union Against Cancer (FIGO) that was enacted in 2002,we divid the samples in: Ⅰstage 16 cases,Ⅱstage 12 cases,Ⅲstage 21 cases,Ⅳstage 11 cases.comparison group is 20 cases of adjacent normal lung tissue (from cancer were more than 3cm).2.2 Experimental |methods Methods is the SP Immunohistochemical method.2.3 Assessing result2.3.1 y-synuclein We require immunohistochemical products staining in the cytoplasm or the nucleus appears yellow particles as a positive criterion. The dye were divided into three stages:no color(1 stage) assess 0 point, light yellow (2 stage) assess the 2 points, brownish yellow (3 stage) assess 3 point; Counting 100 cells every visual field under high power lens(400 times),and counting 5 visual fields of every sample. High magnification of positively stained cells according to the number of accounts to judge the percentage of the total number of cancer cells, positive cells < 25% as one stage (point),26% to 75% as two stage (point),≥76% as three stage (point).The final score for each slice multiplied by two score (1 point to 9 points), final score greater than 7 points as the positive (+),less than 7 points for the negative expression(-).2.3.2 TFPI-2:We require immunohistochemical products staining in the cytoplasm or the nucleus appears yellow particles as a positive criterion. Counting 100 cells every visual field under high power lens(400 times),counting 5 visual fields.no stain or the percentage≤25% as negative(-),25%～50% as weakly positive (+),>50% as strong positive(++)..2.4 Treatment in statistics:Using chi-square test and exact probabilities in 2×2 table, using SPSS 13.0 package, a=0.05 for the test level.3 Result3.1 The expression of y-synuclein and TFPI-2 in NSCLC The result of immunohistochemistry displayed that y-synuclein mainly located in the cytoplasm, nucleus occasionally,in 60 cases of NSCLC tissues the expression of y-synuclein-positive rate was 46.7% (28/60), in 20 cases of normal lung tissues there was none of the positive expression (0%), the difference was statistically significant (P=0.000). TFPI-2 immunohistochemistry positive products were mainly located in the cytoplasm.In 60 cases of NSCLC tissues the expression of TFPI-2 positive rate was 65% (39/60),20 cases of normal lung tissue were positive expression(100%), the difference was statistically significant (P=0.002).3.2 The relation of y-synuclein and TFPI-2 with the clinical path-character High differentiation of NSCLC patients in the y-synuclein positive expression rate was 34.8%, poorly differentiated was 85.7%,the difference was statistically significant (P=0.001).TNM stageⅠ,Ⅱperiod of NSCLC patients with y-synuclein positive expression rate was 28.6%,Ⅲ,Ⅳpatients with y-synuclein positive expression rate was 62.5%,the difference was statistically significant (P=0.009).With lymph node metastasis in NSCLC patients with y-synuclein positive expression rate was 87.5%, non-patients with lymph node metastasis was 19.4%, the difference was statistically significant (P=0.000). The expression rate of y-synuclein was not related to the patient's age, sex, tumor size, pathologic type, clinical type, whether pleural effusion or smoking.TNM stageⅠ,Ⅱperiod of TFPI-2 in NSCLC patients with positive expression rate was 78.6%,Ⅲ,Ⅳpatients with TFPI-2 positive expression rate was 53.1%,the difference was statistically significant (P=0.039).With lymph node metastasis in NSCLC patients with TFPI-2 positive expression rate was45.8%, without lymph node metastasis was 77.8%, the difference was statistically significant (P=0.011).The expression rate of TFPI-2 was not related to the patient's age,sex,tumor size,degree of differentiation,pathologic type,clinical type,whether pleural effusion or smoking.4 Conclision(1)The expression rate of y-synucleinin in NSCLC increased significantly than nomal tissues, suggesting that they were close correlation.γ-synucleinin may become a new diagnostic marker for NSCLC.(2) The espression rate of y-synuclein was close related to the differentiation,TNM stage,lymph node metastasis and has nothing to the patient's age, sex, tumor size, pathologic type, clinical type, whether pleural effusion or smoking.(3)The expression of TFPI-2 in NSCLC was low and appears lower with the TNM staging increased and lymph node metastasis.and was not related to the patient's age,sex,tumor size,pathologic type,differentiation,clinical type,whether pleural effusion or smoking. (4) The abnormal expression ofγ-synuclein and TFPI-2 in NSCLC patients' early diagnosis and prognosis provide a reliable basis and provide a new treatment target.